Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses Additional RNAi Patent Applications

NEW YORK, July 29 - Alnylam Pharmaceuticals of Cambridge, Mass., has licensed two groups of patent applications related to RNA interference technology, the company said today.


The first is an exclusive therapeutic license to US Patent Application No. 20030027783, "Inhibiting gene expression with dsRNA," which describes inventions by Magdalena Zernicka-Goetz and colleagues at University of Cambridge that concern "the specific inhibition of gene expression in mammals by bringing the target into contact with double stranded RNA (dsRNA)," according to the application. Alnylam licensed the application, which was published February 6, from Cancer Research Technology of the UK, a licensing arm of Cancer Research UK and other cancer research institutes.


The company also obtained from MIT an exclusive therapeutic license for patent applications for drug-delivery inventions by MIT scientist Robert Langer that can be applied to RNAi therapeutics.


The company did not disclose the financial terms of the licensing agreements.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.